Parents Funding Rare Disease Cures See Major Breakthroughs

After losing his four-year-old son Cristian to a fatal brain cancer in 2009, John Rivera downsized his business to volunteer 8 hours daily for a foundation bearing his son's name. Now that dedication is paying off with results that seemed impossible just years ago.

The Cristian Rivera Foundation just awarded $365,000 to Dr. Mark Souweidane at Weill Cornell Medicine, its largest single gift since launching. The timing couldn't be more critical: the National Cancer Institute will cease funding the Pediatric Brain Tumor Consortium in March 2026, halting crucial pediatric brain tumor clinical trials.

Only 4% of federal cancer research funding goes to pediatric cancer. Diffuse intrinsic pontine glioma (DIPG), the rare brain cancer that took Cristian's life, affects just 200 to 300 American kids yearly and receives a tiny fraction of that already small slice.

Rivera's foundation has donated over $4 million to DIPG research since 2009, making it one of the largest funders of this work. About 80% comes from individual private donors, with the rest from corporate supporters like Bank of America.

The investment is producing genuine medical progress. Dr. Souweidane now has three patients who have lived longer than five years since their DIPG diagnosis. That's extraordinary when median survival time is just nine to 11 months, and living past two years is exceedingly rare.

The breakthrough came from a novel drug delivery method that bypasses the blood-brain barrier, avoiding toxic side effects while delivering medicine directly to brain tumors. The Cristian Rivera Foundation funded this research continuously when other money dried up.

Why This Inspires

Rare disease research shows what's possible when personal passion meets strategic giving. More than 10,000 rare diseases exist, but only 5% have FDA-approved treatments for the 30 million Americans affected.

In January 2026, another parent-funded victory emerged. Elpida Therapeutics secured an $8 million grant from the California Institute for Regenerative Medicine to start clinical trials for ELP-02, the first gene therapy drug for CMT4J, an ultra-rare neurodegenerative disease. That state funding only became possible because two parent-founded nonprofits first funded the research that proved the concept could work.

"What these foundations have done is filled a gap in funding," said Dr. Souweidane. "Their level of importance is exaggerated today because the other sources of funding have largely evaporated."

These victories arrive as federal research funding faces deep uncertainty, making privately funded breakthroughs more vital than ever for families waiting for cures.